• In December 2020, Boston Scientific announced the launch of its WallFlex Biliary RX Fully Covered Stent with Controlled Release Technology in the United States. The stent is designed to provide controlled release of a drug to help prevent tissue overgrowth.

• In November 2020, Cook Medical received FDA clearance for its Evolution® Controlled-Release Esophageal Stent. The stent features a dual-layer design that aims to reduce the risk of tissue overgrowth and migration

In this report, the Global Gastrointestinal (GI) Stents Market has been segmented by Product, Material, Disease Type, Application, and Geography.

Global Gastrointestinal (GI) Stents Market, Segmentation by Product

The Global Gastrointestinal (GI) Stents Market has been segmented by Product into Biliary Stent, Duodenal Stent, Colonic Stent, Pancreatic Stent and Esophageal Stent.

The biliary stent segment holds a significant share in the GI stents market due to its critical role in managing biliary obstructions, especially in cases of malignant and benign biliary strictures. This segment accounts for approximately 30% of the market, driven by the increasing prevalence of pancreatic and biliary cancers. Technological advancements in self-expanding metal stents (SEMS) have further boosted demand.

The duodenal stent segment is growing steadily, capturing around 20% of the GI stents market. It is primarily used to relieve malignant gastric outlet obstructions, providing a minimally invasive alternative to surgery. Rising incidences of gastrointestinal cancers and advancements in endoscopic placement techniques are key growth drivers.

With a market share of approximately 18%, the colonic stent segment plays a vital role in managing colorectal obstructions, both preoperatively and palliatively. The increasing use of colorectal stents as a bridge to surgery in colorectal cancer patients is a notable trend enhancing segment growth.

The pancreatic stent segment contributes to around 15% of the total market, with applications focused on preventing and treating pancreatic ductal obstructions. These stents are increasingly utilized in the management of chronic pancreatitis and for post-ERCP complications, aiding in procedural efficacy and patient outcomes.

Accounting for roughly 17% of the market, the esophageal stent segment is crucial for the palliation of esophageal malignancies and strictures. Innovations in biodegradable and fully covered stents are enhancing treatment efficacy, with a growing number of cases supporting its widespread adoption.

Global Gastrointestinal (GI) Stents Market, Segmentation by Material

The Global Gastrointestinal (GI) Stents Market has been segmented by Material into Plastic Stents, Self-Expanding Metal Stents, and Covered Self-Expandable Metallic Stents.

The plastic stents segment accounts for approximately 25% of the GI stents market, offering a cost-effective solution for short-term biliary and pancreatic drainage. These stents are commonly used in endoscopic retrograde cholangiopancreatography (ERCP) procedures and are favored for their ease of placement and removal, particularly in benign conditions.

Comprising around 45% of the market, self-expanding metal stents (SEMS) dominate due to their superior patency rates and durability. These stents are widely used in malignant gastrointestinal obstructions, providing long-term relief and reducing the need for repeat procedures. Their growing adoption is driven by technological innovations and clinical efficacy.

The covered self-expandable metallic stents segment captures nearly 30% of the global market. These stents are preferred for their ability to prevent tumor ingrowth and are particularly useful in cases requiring temporary stent placement. They offer a balance between removability and obstruction prevention, making them a versatile choice in both benign and malignant indications.

Global Gastrointestinal (GI) Stents Market, Segmentation by Disease Type

The Global Gastrointestinal (GI) Stents Market has been segmented by Disease Type into Gastrointestinal Cancer, Biliary Diseases, and Inflammatory Bowel Diseases.

The gastrointestinal cancer segment holds a dominant position in the GI stents market, contributing to around 55% of the total share. The rising incidence of esophageal, colorectal, and gastric cancers globally is fueling demand for minimally invasive stenting solutions. These stents provide effective palliative care by relieving malignant obstructions and enhancing patient quality of life.

Accounting for approximately 30% of the market, biliary diseases are a major driver for GI stent usage. Conditions such as bile duct strictures, gallstones, and cholangiocarcinoma often require stenting for effective management. Increased preference for endoscopic interventions over surgical methods supports growth in this segment.

The inflammatory bowel diseases segment, which includes Crohn’s disease and ulcerative colitis, represents roughly 15% of the GI stents market. Although a smaller segment, its growth is driven by the rising prevalence of chronic gastrointestinal inflammation and the adoption of non-surgical stent placement as a therapeutic approach for strictures associated with these conditions.

Global Gastrointestinal (GI) Stents Market, Segmentation by Application

The Global Gastrointestinal (GI) Stents Market has been segmented by Application into Biliary Disease, Colorectal Cancer, Stomach Cancer and Others.

Biliary disease is a leading application area, representing nearly 40% of the global GI stents market. Stents are commonly used to manage biliary obstructions caused by cholangiocarcinoma, pancreatic cancer, and benign biliary strictures. The increasing demand for non-invasive procedures and growing preference for endoscopic interventions are driving segment growth.

The colorectal cancer segment accounts for approximately 30% of the GI stents market. These stents are essential in relieving malignant obstructions and are often used as a bridge to surgery. Rising global incidence rates of colorectal cancer and advancements in self-expanding stent technology are fueling demand.

Stomach cancer contributes to around 20% of the market, where GI stents are used to treat gastric outlet obstructions. These stents provide palliative relief by enabling the passage of food in patients with advanced gastric malignancies. The segment is growing steadily due to the rising burden of gastric cancer globally.

The "Others" segment comprises roughly 10% of the market and includes applications in conditions like duodenal obstruction, pancreatic duct strictures, and inflammatory bowel disorders. Although smaller in share, this segment benefits from the versatility of stent technology and its application in a wide range of gastrointestinal complications.

Global Gastrointestinal (GI) Stents Market, Segmentation by Geography

In this report, the Global Gastrointestinal (GI) Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Gastrointestinal (GI) Stents Market Share (%), by Geographical Region, 2024

North America dominates the global GI stents market, accounting for approximately 35% of the total share. High prevalence of gastrointestinal cancers, advanced healthcare infrastructure, and early adoption of innovative stenting technologies contribute to the region's leading position. The presence of major industry players further boosts market growth.

Europe holds around 25% of the GI stents market, supported by a strong network of specialized healthcare facilities and growing cases of colorectal and biliary diseases. The region also benefits from government healthcare initiatives and increasing adoption of minimally invasive procedures.

Asia Pacific represents nearly 20% of the market, driven by a large patient population and rising awareness about endoscopic treatments. Emerging economies like China and India are experiencing rapid growth due to improving healthcare access and an increasing burden of gastric and liver cancers.

The Middle East and Africa region contributes around 10% to the GI stents market. Growth is supported by expanding medical tourism, rising investment in healthcare infrastructure, and the increasing prevalence of digestive disorders. However, access to advanced treatment options remains a challenge in several areas.

Latin America accounts for about 10% of the global market. The demand is fueled by a growing number of gastrointestinal cancer cases and gradual improvements in diagnostic and therapeutic facilities. Countries like Brazil and Mexico are key contributors to regional market expansion.